# | Title | Journal | Year | Citations |
---|
1 | Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations | Journal of Pain | 2008 | 2,564 |
2 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study | Lancet Oncology, The | 2009 | 2,404 |
3 | SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase | Proceedings of the National Academy of Sciences of the United States of America | 2001 | 2,350 |
4 | Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia | Blood | 2017 | 1,173 |
5 | International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts | Blood | 2015 | 982 |
6 | The evolution of thalidomide and its IMiD derivatives as anticancer agents | Nature Reviews Cancer | 2004 | 731 |
7 | Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2013 | 710 |
8 | Rhinosinusitis: Establishing definitions for clinical research and patient care | Journal of Allergy and Clinical Immunology | 2004 | 705 |
9 | Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide | Leukemia | 2012 | 668 |
10 | Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS | Nature | 2015 | 648 |
11 | Microbial species delineation using whole genome sequences | Nucleic Acids Research | 2015 | 609 |
12 | Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells | Science Translational Medicine | 2012 | 555 |
13 | Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha | Journal of Immunology | 1999 | 553 |
14 | Differential Cytokine Modulation and T Cell Activation by Two Distinct Classes of Thalidomide Analogues That Are Potent Inhibitors of TNF-α | Journal of Immunology | 1999 | 542 |
15 | Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications | Leukemia | 2001 | 536 |
16 | Enantioselective Catalytic Formation of Quaternary Stereogenic Centers | European Journal of Organic Chemistry | 2007 | 523 |
17 | Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN | British Journal of Haematology | 2014 | 505 |
18 | Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) | Journal of the American Academy of Dermatology | 2015 | 498 |
19 | Structural Remodeling of the Human Colonic Mesenchyme in Inflammatory Bowel Disease | Cell | 2018 | 454 |
20 | A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q | Blood | 2011 | 424 |
21 | A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase | Nature | 2016 | 414 |
22 | Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma | JAMA Oncology | 2017 | 405 |
23 | Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells | Clinical Cancer Research | 2008 | 401 |
24 | Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2) | British Journal of Dermatology | 2015 | 384 |
25 | Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs | Nature Structural and Molecular Biology | 2014 | 383 |
26 | Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor | Annals of the Rheumatic Diseases | 2014 | 372 |
27 | The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells | Cancer Immunology, Immunotherapy | 2009 | 362 |
28 | Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma | Leukemia | 2009 | 350 |
29 | Apremilast mechanism of action and application to psoriasis and psoriatic arthritis | Biochemical Pharmacology | 2012 | 346 |
30 | Apremilast, a cAMP phosphodiesterase‐4 inhibitor, demonstrates anti‐inflammatory activity in vitro and in a model of psoriasis | British Journal of Pharmacology | 2010 | 344 |
31 | Nrf2: A Potential Molecular Target for Cancer Chemoprevention by Natural Compounds | Antioxidants and Redox Signaling | 2006 | 337 |
32 | Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma | Blood | 2018 | 335 |
33 | Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes | New England Journal of Medicine | 2020 | 335 |
34 | Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production | Bioorganic and Medicinal Chemistry Letters | 1999 | 331 |
35 | Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis | Haematologica | 2018 | 329 |
36 | Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study | Blood | 2014 | 327 |
37 | A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis | Leukemia | 2019 | 313 |
38 | Rare Disease Terminology and Definitions—A Systematic Global Review: Report of the ISPOR Rare Disease Special Interest Group | Value in Health | 2015 | 311 |
39 | A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines | PLoS ONE | 2010 | 310 |
40 | Development of targeted protein degradation therapeutics | Nature Chemical Biology | 2019 | 303 |
41 | Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response | Blood | 2017 | 300 |
42 | Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases | Nature Genetics | 2020 | 298 |
43 | The standard operating procedure of the DOE-JGI Microbial Genome Annotation Pipeline (MGAP v.4) | Standards in Genomic Sciences | 2015 | 287 |
44 | Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects | British Journal of Cancer | 2002 | 280 |
45 | AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma | Journal of Clinical Oncology | 2019 | 277 |
46 | A 90-day oral gavage toxicity study of d-methylphenidate and d,l-methylphenidate in Sprague–Dawley rats | Toxicology | 2002 | 265 |
47 | Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis | Journal of Clinical Oncology | 2013 | 265 |
48 | Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib | Blood | 2019 | 262 |
49 | Trends in overall survival and costs of multiple myeloma, 2000–2014 | Leukemia | 2017 | 257 |
50 | Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial | Lancet Oncology, The | 2019 | 254 |